Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Shi, Qing; Tebben, Andrew; Dyckman, Alaric J; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R; McIntyre, Kim W; Olini, Gilbert C; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H; Tino, Joseph; De Lucca, George V.
Bioorg Med Chem Lett
; 24(9): 2206-11, 2014 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-24685542
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Structural basis for the recognition of c-Src by its inactivator Csk.
Discovery of novel BTK inhibitors with carboxylic acids.
Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.
Quantitating drug-target engagement in single cells in vitro and in vivo.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors.
Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.